Cholinergic · C14H26N4O11P2 · 488.32 g/mol · CAS 987-78-0
Citicoline (CDP-choline) is a unique choline source that also donates cytidine, supporting both acetylcholine production and the long-term health of neuronal membranes.
When you ingest citicoline, it splits in the intestine into choline and cytidine, both of which independently cross the blood-brain barrier. The choline is used to make acetylcholine and phosphatidylcholine; the cytidine converts to uridine, which is incorporated into neuronal membrane phospholipids and supports dopamine D2 receptor density. The net effect is a slower, more structural cognitive benefit on top of the immediate acetylcholine boost.
250-500mg per serving. Cognizin® branded citicoline is the form used in most peer-reviewed trials.
Citicoline has an excellent safety profile across decades of clinical use, including in stroke recovery patients. Side effects are rare and typically limited to mild GI upset.
Alpha-GPC tends to act faster and feels more acute; citicoline has a more sustained, structural effect and the bonus uridine pathway. Many high-end nootropic stacks (including Plopii Focus Pouches) include both.
Cognizin® is a branded, patented form of citicoline manufactured by Kyowa Hakko. The active molecule is identical to generic citicoline but Cognizin® is the form used in most published clinical trials.
Citicoline is not a stimulant. It supports the systems that stimulants tax. The strongest cognitive effect is achieved by stacking citicoline with a moderate dose of paraxanthine or caffeine.
These statements have not been evaluated by the FDA. Plopii products are not intended to diagnose, treat, cure, or prevent any disease.